NEW YORK (GenomeWeb News) – Moscow-based global investment firm Rostock Group said it has opened a new genomics research center that will carry out wide-scale genetic research in the area of neurodegenerative human diseases.
"The immediate objective of the center is to search for new diagnostics and treatments for Alzheimer's disease, schizophrenia, and other ailments with a significant genetic component in pathogenesis. In particular, the research team will reveal respective gene mutations and develop target-specific pharmaceuticals for the diseases," Rostock said in a statement.
The center's research will be led by Evgeny Rogaev, a Russian State Prize winner, and a developer of methods for individual genomic identifications and discoverer of Alzheimer's disease variants. Last year, he and his team published research that identified a gene as the cause of the Royal Disease, a form of hemophilia transmitted from Queen Victoria to European royal families.
According to Rostock, the genomics center has the only Illumina HiSeq 2000 DNA sequencer in Russia, and will closely collaborate with the N. I. Vavilov Institute of General Genetics of the Russian Academy of Sciences.
The genomics center is an entity of Rostock Biotech Research, a subsidiary of Rostock Group.